# Inhibitor Therapeutics

Inhibitor Therapeutics is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed
- **Website:** inhibitortx.com
- **LinkedIn:** https://www.linkedin.com/company/inhibitor-therapeutics-inc

## Regulatory record

- **Reports private funds:** No

## About

Inhibitor Therapeutics, Inc. trades publicly under the ticker OTCQB:INTI. The company develops and commercializes therapies for patients with cancer and non-cancerous proliferation disorders.

## Sectors

- Biotech
- Pharmaceuticals

## Questions

### What is Inhibitor Therapeutics' lead drug program?

The company's primary program involves repurposing bortezomib, a proteasome inhibitor, for relapsed or refractory multiple myeloma. It has not reported Phase III trial data or regulatory submissions.

### Who manages investment decisions at Inhibitor Therapeutics?

The company has not identified a CEO, CIO, or investment team in public filings. Its executive management and board composition are not disclosed in a way that clarifies investment authority.

### Does Inhibitor Therapeutics have any institutional investors?

The firm has not publicly named any institutional or accredited investors. Its stock trades on the OTC market, which does not require disclosure of major holders.

## Related profiles

- [Nixxy, Inc.](https://altss.com/profile/nixxy-inc)
- [Theriva Biologics, Inc.](https://altss.com/profile/theriva-biologics-inc)

---

Last updated: 2026-07-11T16:26:28.000Z

Canonical page: https://altss.com/profile/inhibitor-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology